You are here

Study Evaluating IMA-638 in Asthma

Last updated on December 6, 2018

FOR MORE INFORMATION
Study Location
Denver, Colorado, 80230 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Asthma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-50 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Men and women of non-childbearing potential with mild to moderate asthma as defined by
forced expiratory volume in 1 second (FEV1) greater than 70% predicted.

- Well controlled asthma, as exhibited by completion of asthma questionnaire.

- Otherwise healthy, except for asthma.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Men and women of non-childbearing potential with mild to moderate asthma as defined by
forced expiratory volume in 1 second (FEV1) greater than 70% predicted.

- Well controlled asthma, as exhibited by completion of asthma questionnaire.

- Otherwise healthy, except for asthma.

NCT00339872
Pfizer
Completed
Study Evaluating IMA-638 in Asthma

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Study Evaluating IMA-638 in Asthma
Randomized, Double-Blind, Placebo-Controlled, Sequential-Group, Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IMA-638 Administered Subcutaneously and Intravenously to Subjects With Asthma
The purpose of this study is to evaluate the safety of, and blood drug levels for, single, ascending doses of IMA-638 in mild to moderate asthma subjects.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Diagnostic
Asthma
Drug: IMA-638
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
April 2007
Not Provided

Inclusion Criteria:

  • Men and women of non-childbearing potential with mild to moderate asthma as defined by forced expiratory volume in 1 second (FEV1) greater than 70% predicted.
  • Well controlled asthma, as exhibited by completion of asthma questionnaire.
  • Otherwise healthy, except for asthma.
Sexes Eligible for Study: All
18 Years to 50 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00339872
3174K1-100
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
December 2007

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now